StockData

TFA Therapeutics, Inc. (RAJAF) stock

RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026Score 7/30
$9.18+0.00 (0.00%)

Close on Oct 16, 2026Market cap –P/E –Yield –

TFA Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

TFA Therapeutics's revenue for the twelve months ending Dec 31, 2023 was $882.53K. For fiscal 2025 it was $1.25M, down 0.6% from the year before. The highest annual figure on record is $1.25M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.25M-0.6%
FY2024Dec 31, 2024$1.25M+42.0%
FY2023Dec 31, 2023$882.53K+1555.7%
FY2022Dec 31, 2022$53.30K-93.9%
FY2021Dec 31, 2021$879.32K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$315.50K–

More TFA Therapeutics figures

See a number that looks wrong?